Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Skye Bioscience, Inc.NMUS · Entity 8098 | CFO and Secretary | July 23, 2018 | July 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Skye Bioscience, Inc.
Report date July 23, 2018 · Filed July 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 643,501 |
Reported balance
After 2018-07-23 transaction · row 1
1 source rowRow 1 · 2018-07-23 · Grant · Acquired 643,501 · Balance 643,501 F1: 100% of the restricted stock award shall vest and be deliverable on April 23, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2028-07-23 | Direct | 1,195,073 |
Reported balance
After 2018-07-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-07-23 · Grant · Acquired 1,195,073 · Balance 1,195,073 F2: 25% of the total number of shares subject to the option shall vest and become exercisable on July 23, 2018, and the remaining 75% of the total number of shares subject to the option shall vest and become exercisable 1/33rd on each of the next 33 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the restricted stock award shall vest and be deliverable on April 23, 2020.
F2: 25% of the total number of shares subject to the option shall vest and become exercisable on July 23, 2018, and the remaining 75% of the total number of shares subject to the option shall vest and become exercisable 1/33rd on each of the next 33 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2018 Filed Jul 23, 2018 21:18 UTC | Skye Bioscience, Inc. NMUS · Entity 8098 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,195,073 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001209191-18-043633 · doc4.xml · derivative · entry 2 Cesario Douglas A · CIK 0001738287 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,195,073 Underlying: Common Stock · 1,195,073 shares Expires 2028-07-23 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option shall vest and become exercisable on July 23, 2018, and the remaining 75% of the total number of shares subject to the option shall vest and become exercisable 1/33rd on each of the next 33 months thereafter. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 21:18 UTC | Skye Bioscience, Inc. NMUS · Entity 8098 | GrantCommon Stock | 643,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-043633 · doc4.xml · nonDerivative · entry 1 Cesario Douglas A · CIK 0001738287 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,501 F1 · kind: 100% of the restricted stock award shall vest and be deliverable on April 23, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.